[1] Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials. Retrieved July 27, 2023, from网页链接 @药明康德内容团队编辑 本文来自药明康德...
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials Save July 27, 2023 6:45 am ET T...
the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults. Retrieved June 21, 2022 from https://www.merck.com/news/merck-presents-positive-results-from-phase-1-2-study-evaluating-v116-the-companys-investigational-pneumococcal-conjugate-vaccine-for-adults/ ...
V116是一款23价疫苗,其中所包含的未被任何当前许可的肺炎球菌疫苗所覆盖的8种血清型占到了肺炎球菌病负担的30%以上。 2022年06月22日讯 /生物谷BIOON/ --默沙东(Merck & Co)近日在2022年肺炎球菌与肺炎球菌病国际研讨会(ISPPD-12)上公布了1/2期V116-001研究的阳性结果。该研究在没有接种过肺炎球菌疫苗的18...
We aimed to assess the safety, tolerability, and immunogenicity of V116, an investigational 21-valent PCV designed for adults. Methods This randomised, double-blind, active comparator controlled, international phase 3 trial enrolled adults with or without stable chronic medical conditions at 112 ...
重要的是,V116中所包含的未被任何当前许可的肺炎球菌疫苗所覆盖的8种血清型占到了该疾病负担的30%以上。”(生物谷Bioon.com) 原文出处:Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults...
重要的是,V116中所包含的未被任何当前许可的肺炎球菌疫苗所覆盖的8种血清型占到了该疾病负担的30%以上。”(生物谷Bioon.com) 原文出处:Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company’s investigat...
重要的是,V116中所包含的未被任何当前许可的肺炎球菌疫苗所覆盖的8种血清型占到了该疾病负担的30%以上。”(生物谷Bioon.com) 原文出处:Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults...
重要的是,V116中所包含的未被任何当前许可的肺炎球菌疫苗所覆盖的8种血清型占到了该疾病负担的30%以上。”(生物谷Bioon.com) 原文出处:Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults...